Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$18.7MCash, Jun 2026
9moCash Runway (est.)
+20%Share Count, 1 Year
Follow GNLX by emailGet an email when GNLX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GNLX, unsubscribe in one click. Privacy
📣 What GNLX Says Is Next
second half of 2026 · “Topline data from the Phase 3 platinum-resistant/refractory ovarian cancer trial (OnPrime/GOG-3076) expected in second half of 2026 About Olvi-Vec Olvi-Vec (olvimulogene nanivacirepvec), Genelux’s lead investigational asset, is a proprietary, modified vaccinia virus being evaluated as an oncolytic immunotherapy.”
Company press release, Jan 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
GNLX reported $18.7M in cash and short-term investments (as of Jun 30, 2026) and used about $6.3M/quarter in operations, an estimated runway of 8.9 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNLX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.